Blair Tyson serves as a subject matter expert in sterile drug products and is part of the strategic manufacturing concept group (SMCG).
Blair is responsible for front-end conceptual design for drug product process design applications, with specific expertise in a variety of parenteral fill-finish dosage forms such as: aseptic/terminally sterilised serum, lyophilized, suspensions, and LVP/SVP. He is also an expert in associated drug delivery systems such as vials, syringes, ampules, cartridges, IV bags, form-fill-seal, and infusion devices. Blair provides operational infrastructure consulting such as manufacturing organisational design, business enterprise systems, technology assessment, equipment & facility integration, and global regulatory compliance services.
Blair was formerly Senior Manager, Parenteral Operations for Eisai Inc. located in Research Triangle Park, NC. For five years he was responsible for managing operational personnel and all manufacturing resources associated with the production of aseptic oncology drug products.
From 2007 through 2011, Blair served as the Senior Manager, Site Engineering for Eisai Inc. responsible for design, construction and commissioning of the greenfield parenteral facility. He developed state-of- the-art aseptic manufacturing processes, started the parenteral business unit including fill-finish, visual inspection and secondary packaging departments, and authored critical business enterprise documents for commercial production. These efforts culminated with successful preauthorization inspection (PAI) audits by the FDA, EMA and JP-FDA as well as multiple product licensures around the world.
Before joining Eisai, Blair worked for Mallinckrodt Medical for 21 years in operations management, process/facility engineering, validation management and R&D positions. He served on the ISPE board of directors for the Carolina - South Atlantic chapter and has been a speaker at numerous ISPE and PDA symposia in the US and Europe.
Blair received a BS in Mechanical Engineering from North Carolina State University and a Masters of Business Administration from Duke University.
What’s your view on the industry?
"Our growing understanding of fundamental physiological disease states, combined with the advancement of novel drug formulations, has propelled the development of new life saving therapies at a rate faster than ever before. The advent of biotechnology-based protein expressions and personalised medicine are exciting advancements that continue to inspire breakthrough discoveries in our industry. It is an especially exciting time for the next generation of scientists and engineers to be involved in the pharmaceutical industry, as new life enhancing drugs and treatments are being discovered that will benefit human healthcare well into the future. We, at NNE, contribute significantly to advances in healthcare by fostering new technologies and supporting investment by our biopharma clients with designs and infrastructure capabilities that are needed to build upon previous science and discovery."
Why do you work in this industry?
"Working in a field that has a direct positive impact on the lives of peoples around the world is very gratifying. Previously working for a company that manufactures drugs that treat cancer and malaria - life altering drugs that benefit millions of people’s lives – was personally fulfilling. Contributing to this industry has been spiritually motivating and made working hard every day a rewarding career choice. After over 35 year in the field of pharmaceuticals, I continue to derive satisfaction from working with like-minded colleagues and helping to grow and improve our industry."
Connect on LinkedIn